Goldman Sachs analyst Matthew Sykes maintained a Hold rating on Nautilus Biotechnolgy (NAUT – Research Report) today and set a price target of $2.00. The company’s shares closed last Wednesday at $2.89, close to its 52-week low of $2.53.
According to TipRanks.com, Sykes has 0 stars on 0-5 stars ranking scale with an average return of -13.4% and a 43.2% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Sema4 Holdings, and Mettler-Toledo.
Nautilus Biotechnolgy has an analyst consensus of Moderate Buy, with a price target consensus of $6.33, implying an 119.8% upside from current levels. In a report released today, Morgan Stanley also maintained a Hold rating on the stock with a $6.00 price target.
Based on Nautilus Biotechnolgy’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.76 million. In comparison, last year the company had a GAAP net loss of $8.41 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NAUT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ARYA Sciences Acquisition Corp III is a blank check company.
Read More on NAUT:
- Nautilus Biotechnolgy (NAUT) Gets a Hold Rating from Morgan Stanley
- Oak Street Health (OSH) Gets a Hold Rating from UBS
- Phathom Pharmaceuticals (PHAT) Gets a Hold Rating from Goldman Sachs
- Morgan Stanley Maintains Their Hold Rating on TransMedics Group (TMDX)
- RBC Capital Reaffirms Their Hold Rating on SolarWinds (SWI)